about
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathologyHead-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In VitroBone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis developmentAbsence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient miceDeficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profileHyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in AtherosclerosisWound administration of M2-polarized macrophages does not improve murine cutaneous healing responses.Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice.BMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality.Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice.Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice.Rupture of the atherosclerotic plaque: does a good animal model exist?Nuclear factor kappaB signaling in atherogenesis.Nuclear factor kappa B signaling in macrophage function and atherogenesis.Arginase-1 deficiency regulates arginine concentrations and NOS2-mediated NO production during endotoxemia.Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease.Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance.Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies.Macrophage polarization: the epigenetic point of view.Epigenetic mechanisms of macrophage activation in type 2 diabetes.Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis.Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells.Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.Immune Modulation of Brown(ing) Adipose Tissue in Obesity.Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis.Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice.High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis.Lipopolysaccharide-induced gene expression in murine macrophages is enhanced by prior exposure to oxLDL.Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages.BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice.IFN-γ priming of macrophages represses a part of the inflammatory program and attenuates neutrophil recruitment.Dectin-1 deficiency does not affect atherosclerosis development in mice.Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque composition by shifting the balance from inflammation toward fibrosis.Macrophage microRNA-155 promotes cardiac hypertrophy and failure.The IgM response to modified LDL in experimental atherosclerosis: hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies.Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice.Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study.Deleting myeloid IL-10 receptor signalling attenuates atherosclerosis in LDLR-/- mice by altering intestinal cholesterol fluxes.
P50
Q24317282-ABE8C1C2-C032-4F63-AC8F-43DC5EE2861FQ28551910-08C2B588-3B6C-4AAE-8A5F-B0A27D4E202FQ28731544-8EAA7C9C-5B7D-4754-96DC-C274F2D807AEQ33479145-6CF87CB5-47ED-4A31-821A-5C724341F39FQ33656103-55C94282-14A5-4586-BA34-666516947E1DQ33856678-CF8F7FCB-104F-4AF3-A0A7-16152E17D669Q33961310-690454C5-1A3F-4DF3-8DFA-C940E5354E83Q34256848-D184312E-63EF-4600-8E9D-906B7087113CQ34997193-C3A0137C-8293-4814-AF5A-F2407F8898B6Q35029725-685AAA6D-DC3B-4BBA-8076-00DFC0277607Q35044164-613ECE7E-F7FA-44ED-A62D-75FC315EE615Q35077352-1A07C8E3-B85D-4DD8-9B3C-4498816FE8D5Q36054434-B6B70631-1EF5-4128-9F5B-103721E56CA4Q36251713-FDEF0D04-274C-46CF-ACFF-B9C57F38BDEAQ37500202-18CB5826-51AC-4708-B899-E18F72C903BCQ37557637-CCE94533-0EA3-4DF6-8186-CBE97BFC10FAQ37599837-15AB15AF-F442-422B-81ED-6C8792119D23Q37737112-29583569-A6E2-43BE-9CE7-9D444D8A57E6Q38175375-A0058FD0-BD11-4B3B-93D8-15AD6FB5DD5FQ38246096-DEB349A6-F64B-4271-8230-8FC15A16F191Q38822726-96311346-1ADA-40AF-A486-840713357160Q38890074-A3485C9C-EA49-4974-8C85-CE824CDA1EC5Q38891314-DB13C946-6C0B-4E74-A5D6-ABCF86EE5393Q38935747-73CB7E0F-CC7D-46F8-BD4A-10857299BEEEQ39010070-DCBEF15C-9F0D-4985-B051-CCC99ACF6C17Q39162364-26D8DA51-87F7-4506-A6EA-AB5A7D1CEFE6Q39348833-4EB96987-9239-4B95-B74B-3F2FC1FF6F1FQ39961306-37A5430F-E525-4127-926C-D2B4044D3C4AQ40221233-27E5152F-A084-48A1-896B-0ED41862C8CAQ40255872-841D98BA-8137-4C3F-A066-781446C06800Q40509286-6849B31D-3001-4A13-9D92-B101FDF7717BQ40656795-9F9026E0-19DB-4807-80B3-6793CC1A8101Q41270235-B4529A8F-E928-48E8-A6B0-44C978A1CB61Q41435964-B086EE27-8366-46DF-A975-DDB5CA72F159Q41467610-BEB944F6-4697-4C5D-B5B3-3F14C8913B9EQ42250729-1B22ECAF-DAED-440E-BEA2-C99B606046B2Q43275860-8CF5F04F-D47C-4D16-BDA2-989A83FE02A2Q45923975-A760C5F7-61BF-4FEE-BD11-C21FBC62C710Q46553696-3D5D5ED5-806C-4168-8B74-B2668A904B36Q50881990-B43E445F-3AE3-4BC1-94AB-1B8E8EF00480
P50
description
researcher ORCID ID = 0000-0002-4038-6636
@en
wetenschapper
@nl
name
Menno de Winther
@ast
Menno de Winther
@en
Menno de Winther
@nl
type
label
Menno de Winther
@ast
Menno de Winther
@en
Menno de Winther
@nl
prefLabel
Menno de Winther
@ast
Menno de Winther
@en
Menno de Winther
@nl
P106
P21
P31
P496
0000-0002-4038-6636